Intervention
Bimatoprost 0.01% ophthalmic solution
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownAn Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®NCT01664039 · 2012-09-01
COMPLETEDObservational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)NCT01568008 · 2011-10-01
COMPLETEDAssessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)NCT01464424 · 2011-10-01
COMPLETEDSafety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular HypertensionNCT00652496 · 2005-01-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED4
Phase mix
PHASE42
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.